Jasper Therapeutics is a clinical-stage biotechnology company developing targeted therapeutics for mast cell-driven diseases, including chronic urticaria and allergic asthma. The company's lead product candidate, briquilimab, is a humanized monoclonal antibody that blocks the stem cell factor (SCF) pathway to deplete mast cells throughout the body, with clinical trials demonstrating favorable safety profiles and evidence of efficacy across multiple indications. Jasper operates under exclusive worldwide license agreements with Amgen for development and commercialization of briquilimab and competes against other mast cell modulation approaches through a differentiated mechanism offering potential advantages in durability and breadth of therapeutic effect.